CLOs on the Move

Standard Bio

www.standardbio.com

 
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.standardbio.com
  • 2 Tower Place Suite 2000
    South San Francisco, CA USA 94080
  • Phone: 650.266.6000

Executives

Name Title Contact Details
Michael Bastian
 Chief Intellectual Property Counsel Profile
Agnieszka Gallagher
 Chief Legal Officer Profile
Nicholas Khadder
 SVP, General Counsel and Corporate Secretary Profile

Similar Companies

Schleicher and Schuell BioScience

Schleicher & Schuell BioScience is a Keene, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifesprout

Revolutionary Products for Soft Tissue Replacement and Regeneration

ActaCell

ActaCell is a Austin, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sensei Biotherapeutics

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Carterra

Carterra, formerly Wasatch Microfluidics, develops high throughput surface plasmon resonance array-based platforms for biomolecular interaction analysis.